RECRUITING

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

Official Title

A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Quick Facts

Study Start:2024-08-30
Study Completion:2028-11-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06425302

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Local Institution - 0152
Birmingham, Alabama, 35294-3300
United States
Alaska Oncology and Hematology
Anchorage, Alaska, 99508
United States
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona, 85054
United States
Local Institution - 0190
Tucson, Arizona, 85711
United States
Local Institution - 0035
San Francisco, California, 94143
United States
Local Institution - 0022
Washington, District of Columbia, 20007
United States
Local Institution - 0209
Fort Myers, Florida, 33901
United States
Mayo Clinic in Florida
Jacksonville, Florida, 32224
United States
Local Institution - 0210
Saint Petersburg, Florida, 33705
United States
Tampa General Hospital
Tampa, Florida, 33606
United States
Local Institution - 0208
West Palm Beach, Florida, 33401
United States
The University of Kansas Cancer Center - Westwood
Westwood, Kansas, 66205
United States
Local Institution - 0173
Jefferson, Louisiana, 70121
United States
Local Institution - 0033
Baltimore, Maryland, 21287
United States
Local Institution - 0001
Boston, Massachusetts, 02114
United States
Local Institution - 0004
Boston, Massachusetts, 02114
United States
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota, 55905
United States
Comprehensive Cancer Centers Of Nevada
Henderson, Nevada, 89074
United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601
United States
Local Institution - 0020
New Brunswick, New Jersey, 08903
United States
Local Institution - 0036
New York, New York, 10029
United States
Local Institution - 0052
Salt Lake City, Utah, 84106
United States
Local Institution - 0200
Norfolk, Virginia, 23502
United States
Local Institution - 0201
Norfolk, Virginia, 23502
United States
Local Institution - 0166
Seattle, Washington, 98104
United States
Local Institution - 0202
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Celgene

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-30
Study Completion Date2028-11-27

Study Record Updates

Study Start Date2024-08-30
Study Completion Date2028-11-27

Terms related to this study

Keywords Provided by Researchers

  • Follicular lymphoma
  • Grade 1-3a Follicular lymphoma
  • BMS-986369
  • CC-99282
  • Lymphoma

Additional Relevant MeSH Terms

  • Lymphoma, Follicular